Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph After 7 Days of Repeated Oral Administration in Adult Participants Scheduled for Cochlear Implantation

X
Trial Profile

A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph After 7 Days of Repeated Oral Administration in Adult Participants Scheduled for Cochlear Implantation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Hearing loss; Sensorineural hearing loss
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sensorion
  • Most Recent Events

    • 23 Sep 2024 According to a Sensorion media release, company reported the analysis of the final results during its symposium, held at the World Congress of Audiology, on September 20, 2024.
    • 23 Sep 2024 Results presented in the Sensorian Media Release.
    • 19 Sep 2024 According to a Sensorion media release, full data of this trial is anticipated to be presented at the World Congress of Audiology, on September 20, 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top